Pingzhang Tang
YOU?
Author Swipe
View article: Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Multivariable Cox regression analysis of determinants of PFS
View article: Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Best changes in the sum of longest diameters of target lesions for the anlotinib group and the placebo group. Purplish red: confirmed partial response; blue: stable disease lasting at least 4 week.
View article: Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Multivariable Cox regression analysis of determinants of OS (without consideration of crossover)
View article: Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) Kaplan–Meier estimate of overall survival (OS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 3 mon…
View article: Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) Kaplan–Meier estimate of progress-free survival (PFS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond …
View article: Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Supplementary methods
View article: Bias correction based runoff change attribution quantification for the typical water conservation catchment in the upper yellow river basin
Bias correction based runoff change attribution quantification for the typical water conservation catchment in the upper yellow river basin Open
View article: Hydrophobically modified <scp>Cu<sub>2</sub>O</scp> nanocube for selective <scp>CO<sub>2</sub></scp> electroreduction to <scp>C<sub>2</sub></scp><sub>+</sub> products
Hydrophobically modified <span>Cu<sub>2</sub>O</span> nanocube for selective <span>CO<sub>2</sub></span> electroreduction to <span>C<sub>2</sub></span><sub>+</sub> products Open
The electrochemical conversion of CO 2 into carbonaceous fuels and chemicals emerges as a promising sustainable strategy toward energy‐rich chemical feedstocks. However, CO 2 reduction reaction (CO 2 RR) in aqueous environments is highly i…
View article: Systematic Evaluation and Identification of Anti-Inflammatory and Anti-Aging Ginseng Peptides for Skincare Applications
Systematic Evaluation and Identification of Anti-Inflammatory and Anti-Aging Ginseng Peptides for Skincare Applications Open
This study explores the potential of ginseng-derived peptides (GPs) as multifunctional bioactive agents for skincare. Unlike previous research into ginseng saponins and polysaccharides, we identified that ginseng extracts containing water-…
View article: A comprehensive review on selenium and blood pressure: Recent advances and research perspectives
A comprehensive review on selenium and blood pressure: Recent advances and research perspectives Open
Although some findings indicate that Se might increase BP, its anti-inflammatory, anti-oxidant, anti-vascular remodeling, anti-atherosclerotic, anti-ferroptosis, and regulation of immune response effects suggest that maintaining an appropr…
View article: Bias Correction Based Runoff Change Attribution Quantification for the Typical Water Conservation Catchment in the Upper Yellow River Basin
Bias Correction Based Runoff Change Attribution Quantification for the Typical Water Conservation Catchment in the Upper Yellow River Basin Open
View article: Platinum–copper nanowire networks with enhanced CO tolerance toward methanol oxidation electrocatalysis
Platinum–copper nanowire networks with enhanced CO tolerance toward methanol oxidation electrocatalysis Open
CO-tolerant Pt 42 Cu 58 NWNs enhance the MOR through the modulated d-band center by strain–ligand effects and the stable 3D network structure, overcoming the inherent issues of CO poisoning and structural ripening.
View article: Fraxinellone protects against cardiac injury and decreases ventricular fibrillation susceptibility during myocardial ischemia-reperfusion
Fraxinellone protects against cardiac injury and decreases ventricular fibrillation susceptibility during myocardial ischemia-reperfusion Open
FRA may exert cardioprotective effects during MIRI by inhibiting myocardial inflammation, oxidative stress and apoptosis, and decrease VF susceptibility by improving sympathetic remodeling and ion channel remodeling, which might represent …
View article: 91P A real-world study of tislelizumab (anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
91P A real-world study of tislelizumab (anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma Open
Data on elucidating the efficacy and safety of tislelizumab combined with tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC) are lacking. Herein, we explored the regimen of tislelizumab plus TKIs for intermediate or advanc…
View article: Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Supplementary methods
View article: Data from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Data from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Purpose:Alhough antiangiogenic agents are the bedrock of treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), novel antiangiogenic agents with optimized features like greater target-binding affinities and more …
View article: Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Best changes in the sum of longest diameters of target lesions for the anlotinib group and the placebo group. Purplish red: confirmed partial response; blue: stable disease lasting at least 4 week.
View article: Supplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
The Kaplan-Meier curve of progress-free PFS in the Per-Protocol Set. The tick marks indicate censored data.
View article: Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) Kaplan–Meier estimate of progress-free survival (PFS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond …
View article: Supplementary Figure S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) The Kaplan-Meier curve of overall survival (OS) in the per protocol set. (B) The Kaplan-Meier curve of OS adjusted by a two-stage estimation method based on the rank preserving structural failure time (RPSFT) model. The tick marks indi…
View article: Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Multivariable Cox regression analysis of determinants of PFS
View article: Supplementary Table S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Grade 3 or above treatment-related adverse events (TRAEs)
View article: Supplementary Table S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Representativeness of Study Participants
View article: Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Best changes in the sum of longest diameters of target lesions for the anlotinib group and the placebo group. Purplish red: confirmed partial response; blue: stable disease lasting at least 4 week.
View article: Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Multivariable Cox regression analysis of determinants of OS (without consideration of crossover)
View article: Supplementary Table S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Changes of quality of life throughout the treatment period evaluated by EORTC QLQ-C30.
View article: Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) Kaplan–Meier estimate of overall survival (OS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 3 mon…
View article: Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Supplementary methods
View article: Supplementary Table S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Changes of quality of life throughout the treatment period evaluated by EORTC QLQ-C30.
View article: Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) Kaplan–Meier estimate of overall survival (OS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 3 mon…